NASDAQ:TYME - Tyme Technologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.81 +0.29 (+8.24 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$3.81
Today's Range$3.48 - $3.88
52-Week Range$2.01 - $9.50
Volume408,816 shs
Average Volume291,515 shs
Market Capitalization$385.67 million
P/E RatioN/A
Dividend YieldN/A
Beta0.48

About Tyme Technologies (NASDAQ:TYME)

Tyme Technologies logoTyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company has a co-development agreement with the University of California San Francisco to evaluate SM-88 therapy in prostate cancer. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TYME
CUSIPN/A
Phone646-205-1603

Debt

Debt-to-Equity RatioN/A
Current Ratio6.83
Quick Ratio3.40

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.08 per share
Price / Book47.63

Profitability

EPS (Most Recent Fiscal Year)($0.18)
Net Income$-15,200,000.00
Net MarginsN/A
Return on Equity-153.04%
Return on Assets-118.35%

Miscellaneous

EmployeesN/A
Outstanding Shares101,230,000

Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

What price target have analysts set for TYME?

3 brokers have issued 12-month price objectives for Tyme Technologies' shares. Their predictions range from $7.00 to $9.50. On average, they expect Tyme Technologies' share price to reach $8.25 in the next twelve months. View Analyst Ratings for Tyme Technologies.

What are Wall Street analysts saying about Tyme Technologies stock?

Here are some recent quotes from research analysts about Tyme Technologies stock:
  • 1. Canaccord Genuity analysts commented, "We continue to view SM-88’s ability to generate responses across ~15 solid and liquid tumor types and with durable effect in advanced cancer patients progressing on available therapies as intriguing and reiterate our BUY rating." (6/15/2018)
  • 2. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (4/12/2018)

Who are some of Tyme Technologies' key competitors?

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the folowing people:
  • Mr. Steven E. Hoffman, CEO & Director (Age 55)
  • Mr. Michael S. Demurjian, Chief Operating Officer and Director (Age 51)
  • Mr. Ben R. Taylor, Pres & CFO (Age 41)
  • Dr. Jonathan M. Eckard, Chief Scientific Affairs Officer
  • Dr. Giuseppe Del Priore M.D., MPH, Chief Medical Officer (Age 56)

Has Tyme Technologies been receiving favorable news coverage?

News headlines about TYME stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tyme Technologies earned a daily sentiment score of 0.11 on Accern's scale. They also assigned news stories about the company an impact score of 46.61 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.55%), Farallon Capital Management LLC (1.43%) and Family Management Corp (0.14%). Company insiders that own Tyme Technologies stock include Michael Demurjian and Steve Hoffman. View Institutional Ownership Trends for Tyme Technologies.

Which major investors are buying Tyme Technologies stock?

TYME stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Millennium Management LLC and Family Management Corp. View Insider Buying and Selling for Tyme Technologies.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $3.81.

How big of a company is Tyme Technologies?

Tyme Technologies has a market capitalization of $385.67 million. The company earns $-15,200,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 646-205-1603 or via email at [email protected]


MarketBeat Community Rating for Tyme Technologies (TYME)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  87
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tyme Technologies (NASDAQ:TYME) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Tyme Technologies in the last 12 months. Their average twelve-month price target is $8.25, suggesting that the stock has a possible upside of 116.54%. The high price target for TYME is $9.50 and the low price target for TYME is $7.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.25$8.25$8.25$7.50
Price Target Upside: 116.54% upside94.58% upside94.58% upside127.27% upside

Tyme Technologies (NASDAQ:TYME) Consensus Price Target History

Price Target History for Tyme Technologies (NASDAQ:TYME)

Tyme Technologies (NASDAQ:TYME) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2018Canaccord GenuityReiterated RatingBuyLowView Rating Details
2/8/2018HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $9.50HighView Rating Details
11/17/2017Evercore ISIInitiated CoverageOutperform$7.00N/AView Rating Details
(Data available from 6/17/2016 forward)

Earnings

Tyme Technologies (NASDAQ:TYME) Earnings History and Estimates Chart

Earnings by Quarter for Tyme Technologies (NASDAQ:TYME)

Tyme Technologies (NASDAQ:TYME) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.23 EPS
Next Year EPS Consensus Estimate: $-0.39 EPS

Tyme Technologies (NASDAQ TYME) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q2 2018($0.06)ViewN/AView Earnings Details
8/10/2017Q1 2018($0.03)ViewN/AView Earnings Details
6/12/2017Q4 2017($0.04)ViewN/AView Earnings Details
2/14/2017Q3 2017($0.04)ViewN/AView Earnings Details
8/9/2016Q1 2017($0.07)ViewN/AView Earnings Details
5/10/2016Q4 2016($0.03)ViewN/AView Earnings Details
4/11/2016Q3 2016($0.03)ViewN/AView Earnings Details
11/23/2015Q2 2016($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Tyme Technologies (NASDAQ:TYME) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Tyme Technologies (NASDAQ TYME) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 59.60%
Institutional Ownership Percentage: 9.26%
Insider Trading History for Tyme Technologies (NASDAQ:TYME)
Institutional Ownership by Quarter for Tyme Technologies (NASDAQ:TYME)

Tyme Technologies (NASDAQ TYME) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Michael DemurjianCOOSell400$3.75$1,500.00View SEC Filing  
2/12/2018Steve HoffmanCEOSell17,986$3.82$68,706.52View SEC Filing  
12/11/2017Michael DemurjianCOOSell1,900$3.73$7,087.00View SEC Filing  
11/14/2017Michael DemurjianCOOSell50,000$3.34$167,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tyme Technologies (NASDAQ TYME) News Headlines

Source:
DateHeadline
Tyme Technologies (TYME) Given "Buy" Rating at Canaccord GenuityTyme Technologies (TYME) Given "Buy" Rating at Canaccord Genuity
www.americanbankingnews.com - June 15 at 4:48 PM
Tyme Inc. (TYME) Reports Detailed Data & Analyses with SM-88 on First Human Study & Compassionate Use ProgramsTyme Inc. (TYME) Reports Detailed Data & Analyses with SM-88 on First Human Study & Compassionate Use Programs
www.streetinsider.com - June 13 at 9:49 AM
Tyme Technologies SM-88 shows anti-tumor effect across range of cancers; shares up 10%Tyme Technologies' SM-88 shows anti-tumor effect across range of cancers; shares up 10%
seekingalpha.com - June 12 at 3:54 PM
Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use ProgramsTyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use Programs
finance.yahoo.com - June 12 at 9:51 AM
 Brokerages Expect Tyme Technologies Inc (TYME) to Announce -$0.08 EPS Brokerages Expect Tyme Technologies Inc (TYME) to Announce -$0.08 EPS
www.americanbankingnews.com - June 11 at 9:14 AM
Tyme Appoints Pharma Executive Don DeGolyer to Board of DirectorsTyme Appoints Pharma Executive Don DeGolyer to Board of Directors
feeds.benzinga.com - May 30 at 8:16 AM
Tyme Technologies (TYME) Given Average Rating of "Hold" by AnalystsTyme Technologies (TYME) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 27 at 3:40 AM
Zacks: Brokerages Expect Tyme Technologies (TYME) Will Post Earnings of -$0.08 Per ShareZacks: Brokerages Expect Tyme Technologies (TYME) Will Post Earnings of -$0.08 Per Share
www.americanbankingnews.com - May 24 at 11:10 PM
42 Stocks Moving In Thursdays Mid-Day Session42 Stocks Moving In Thursday's Mid-Day Session
feeds.benzinga.com - May 24 at 3:18 PM
Tyme Announces Five Clinical Abstracts at the 2018 ASCO Annual MeetingTyme Announces Five Clinical Abstracts at the 2018 ASCO Annual Meeting
finance.yahoo.com - May 17 at 10:32 AM
Zacks: Analysts Expect Tyme Technologies (TYME) to Announce -$0.08 Earnings Per ShareZacks: Analysts Expect Tyme Technologies (TYME) to Announce -$0.08 Earnings Per Share
www.americanbankingnews.com - May 7 at 3:14 PM
Tyme Technologies (TYME) Raised to Hold at ValuEngineTyme Technologies (TYME) Raised to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 3:48 PM
Tyme Technologies (TYME) Receives Consensus Recommendation of "Hold" from BrokeragesTyme Technologies (TYME) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 2 at 3:34 AM
Zacks: Tyme Technologies (TYME) Given Consensus Recommendation of "Strong Buy" by BrokeragesZacks: Tyme Technologies (TYME) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 28 at 7:52 AM
Zacks: Brokerages Anticipate Tyme Technologies (TYME) to Post -$0.08 EPSZacks: Brokerages Anticipate Tyme Technologies (TYME) to Post -$0.08 EPS
www.americanbankingnews.com - April 20 at 1:18 PM
 Brokerages Set $8.83 Price Target for Tyme Technologies (TYME) Brokerages Set $8.83 Price Target for Tyme Technologies (TYME)
www.americanbankingnews.com - April 13 at 3:29 AM
Tyme Technologies (TYME) Stock Rating Upgraded by Zacks Investment ResearchTyme Technologies (TYME) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 12 at 2:52 PM
Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018
finance.yahoo.com - April 9 at 10:28 AM
Tyme Inc. (TYME) Announces Sarcoma Treatment Collaboration with The Joseph Ahmed FoundationTyme Inc. (TYME) Announces Sarcoma Treatment Collaboration with The Joseph Ahmed Foundation
www.streetinsider.com - April 6 at 10:55 AM
Tyme and JAF Announce Sarcoma Treatment CollaborationTyme and JAF Announce Sarcoma Treatment Collaboration
finance.yahoo.com - April 6 at 10:55 AM
 Brokerages Expect Tyme Technologies Inc (TYME) Will Post Earnings of -$0.08 Per Share Brokerages Expect Tyme Technologies Inc (TYME) Will Post Earnings of -$0.08 Per Share
www.americanbankingnews.com - April 3 at 3:12 PM
Tyme Technologies (TYME) Research Coverage Started at Canaccord GenuityTyme Technologies (TYME) Research Coverage Started at Canaccord Genuity
www.americanbankingnews.com - March 30 at 8:56 PM
BidaskClub Upgrades Tyme Technologies (TYME) to HoldBidaskClub Upgrades Tyme Technologies (TYME) to Hold
www.americanbankingnews.com - March 30 at 5:40 PM
Tyme Inc. (TYME) Reports First Site Open for Phase II Trial with SM-88 in Pancreatic CancerTyme Inc. (TYME) Reports First Site Open for Phase II Trial with SM-88 in Pancreatic Cancer
www.streetinsider.com - March 30 at 10:19 AM
Tyme Technologies, Inc. Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018Tyme Technologies, Inc. Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
finance.yahoo.com - March 29 at 10:38 AM
 Tyme Technologies Inc (TYME) Receives Average Recommendation of "Strong Buy" from Brokerages Tyme Technologies Inc (TYME) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 29 at 10:29 AM
Tyme Technologies Inc (TYME) Short Interest UpdateTyme Technologies Inc (TYME) Short Interest Update
www.americanbankingnews.com - March 29 at 2:21 AM
Tyme Announces First Site Open for its Phase II Trial with SM-88 in Pancreatic CancerTyme Announces First Site Open for its Phase II Trial with SM-88 in Pancreatic Cancer
finance.yahoo.com - March 27 at 10:39 AM
Tyme Technologies (TYME) Upgraded to "Sell" by BidaskClubTyme Technologies (TYME) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - March 25 at 12:16 AM
-$0.06 Earnings Per Share Expected for Tyme Technologies Inc (TYME) This Quarter-$0.06 Earnings Per Share Expected for Tyme Technologies Inc (TYME) This Quarter
www.americanbankingnews.com - March 17 at 11:25 AM
Active-Investors: Wired News - FDA Accepted Tymes IND Application to Begin Phase-II Clinical Study for SM-88 in Pancreatic CancerActive-Investors: Wired News - FDA Accepted Tyme's IND Application to Begin Phase-II Clinical Study for SM-88 in Pancreatic Cancer
www.finanznachrichten.de - March 17 at 10:35 AM
Pre-Open Movers 03/14: (RKDA) (RFIL) (TYME) Higher; (EARS) (SILC) (SIG) Lower (more...)Pre-Open Movers 03/14: (RKDA) (RFIL) (TYME) Higher; (EARS) (SILC) (SIG) Lower (more...)
www.streetinsider.com - March 14 at 11:37 AM
BRIEF-FDA Acceptance Of IND For Tyme To Begin Phase II Trial In Pancreatic CancerBRIEF-FDA Acceptance Of IND For Tyme To Begin Phase II Trial In Pancreatic Cancer
www.reuters.com - March 14 at 11:37 AM
FDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic CancerFDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic Cancer
finance.yahoo.com - March 14 at 11:37 AM
 Tyme Technologies Inc (TYME) Given $8.83 Average Price Target by Brokerages Tyme Technologies Inc (TYME) Given $8.83 Average Price Target by Brokerages
www.americanbankingnews.com - March 11 at 4:51 PM
Tyme Technologies (TYME) Upgraded to "Sell" at BidaskClubTyme Technologies (TYME) Upgraded to "Sell" at BidaskClub
www.americanbankingnews.com - March 8 at 8:16 PM
Tyme Technologies Announces Closing of Public Offering of Common StockTyme Technologies Announces Closing of Public Offering of Common Stock
finance.yahoo.com - March 8 at 10:49 AM
Tyme Technologies Inc (TYME) Short Interest Up 41.3% in FebruaryTyme Technologies Inc (TYME) Short Interest Up 41.3% in February
www.americanbankingnews.com - March 3 at 3:26 AM
Zacks: Analysts Expect Tyme Technologies Inc (TYME) Will Announce Earnings of -$0.06 Per ShareZacks: Analysts Expect Tyme Technologies Inc (TYME) Will Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - February 28 at 11:39 AM
Tyme Technologies Announces Offering of Common StockTyme Technologies Announces Offering of Common Stock
finance.yahoo.com - February 26 at 4:20 PM
UPDATE: Tyme Inc. (TYME) Names Tommy Thompson to BoardUPDATE: Tyme Inc. (TYME) Names Tommy Thompson to Board
www.streetinsider.com - February 22 at 9:59 AM
Zacks: Analysts Set $8.83 Target Price for Tyme Technologies Inc (TYME)Zacks: Analysts Set $8.83 Target Price for Tyme Technologies Inc (TYME)
www.americanbankingnews.com - February 22 at 5:10 AM
Tyme Technologies Appoints Tommy G. Thompson to Board of DirectorsTyme Technologies Appoints Tommy G. Thompson to Board of Directors
finance.yahoo.com - February 21 at 10:46 AM
Critical Survey: Tyme Technologies (TYME) vs. Bioverativ (BIVV)Critical Survey: Tyme Technologies (TYME) vs. Bioverativ (BIVV)
www.americanbankingnews.com - February 18 at 7:04 PM
Zacks: Tyme Technologies Inc (TYME) Given Average Rating of "Strong Buy" by BrokeragesZacks: Tyme Technologies Inc (TYME) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - February 18 at 5:24 AM
Tyme Technologies (TYME) Downgraded by Zacks Investment ResearchTyme Technologies (TYME) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 15 at 2:44 PM
Insider Selling: Tyme Technologies Inc (TYME) CEO Sells 17,986 Shares of StockInsider Selling: Tyme Technologies Inc (TYME) CEO Sells 17,986 Shares of Stock
www.americanbankingnews.com - February 14 at 9:58 PM
Tyme to Present at RBC Capital Markets 2018 Global Healthcare ConferenceTyme to Present at RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 13 at 8:36 AM
Tyme Technologies Inc (TYME) Expected to Post Earnings of -$0.06 Per ShareTyme Technologies Inc (TYME) Expected to Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - February 11 at 7:08 PM
BRIEF-Tyme Technologies Says To Report Full Phase II Data For SM-88 In Second Half Of 2018BRIEF-Tyme Technologies Says To Report Full Phase II Data For SM-88 In Second Half Of 2018
www.reuters.com - February 9 at 6:01 PM

SEC Filings

Tyme Technologies (NASDAQ:TYME) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Tyme Technologies (NASDAQ:TYME) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tyme Technologies (NASDAQ TYME) Stock Chart for Sunday, June, 17, 2018

Loading chart…

This page was last updated on 6/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.